# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cara Therapeutics plans to explore strategic alternatives. There are no meaningful development programs in the pipeline, analys...
Canaccord Genuity analyst Sumant Kulkarni downgrades Cara Therapeutics (NASDAQ:CARA) from Buy to Hold and lowers the price t...